were determined by a trypan blue exclusion test for cell viability. *P < 0.05. Western blotting with vaccinia virus-specific mouse antiserum (dilution 1:2,000). Normal mouse serum at 1:2,000 dilution was used as specificity control and anti-GAPDH Ab was used as a loading control. Bands were developed with HRP-labeled secondary Abs followed by Clarity Western ECL detection system. One representative blot of two performed is shown. (a) SCID mice (n = 6) were injected i.p. with 2 x 10 6 CAOV2-R cells. Oncolytic virotherapy with OVV-CXCR4-A-Fc, OVV-Fc (2.5 x 10 7 PFU delivered i.p.) or PLD (5 mg/kg) delivered i.v.
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was initiated 10 days later. In parallel experiments, PLD was delivered to virally-treated mice 8 days after virus injection. Control mice were treated with PBS. Tumor progression was monitored by bioluminescence imaging. (b) Kaplan-Meier survival plots were prepared and significance was determined using the log-rank method. *P < 0.05, **P < 0.01, ***P < 0.001.
